1. Scrip
  2. >>Business

Vigilant Hikma bounces from Arab Spring with $200m on hand for acquisitions

 
• By Eleanor Malone

Following the political and social upheaval of the Arab Spring, Hikma Pharmaceuticals is poised for expansion into markets that are now much more receptive than before. Said Darwazah, CEO of the Jordan-based speciality pharma group, told Scrip that while the political disruptions in the Middle East only cut a company-estimated $20 million from sales revenue in 2011, the situation has transformed some markets into an opportunity for accelerated growth.

Following the political and social upheaval of the Arab Spring, Hikma Pharmaceuticals is poised for expansion into markets that are now much more receptive than before. Said Darwazah, CEO of the Jordan-based speciality pharma group, told Scrip that while the political disruptions in the Middle East only cut a company-estimated $20 million from sales revenue in 2011, the situation has transformed some markets into an opportunity for accelerated growth.

"Governments are responding to the Arab Spring by increasing spending on healthcare," observed Mr Darwazah, adding that Hikma was well...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

Finance Watch: Scorpion Spinout Antares Launches With $177m For Precision Medicines

 
• By Mandy Jackson

Private Company Edition: Antares’ lead asset will enter the clinic in 2026 after Lilly committed up to $2.5bn for Scorpion’s Phase I/II PI3Kα inhibitor STX-478. Also, Amplify raised $200m for its first biotech VC fund and Mosanna raised an $80m series A round, among other financings.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.